Phase 1 N=26 Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation
Cannabis Toxicology
Primary: Delta-9-tetrahydrocannabinol (THC) Cmax in Blood — 1.4; 3.07; 0.5 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=24 Age-Related Effects of THC
Tolerance · Adolescent Behavior · THC
Primary: Change From Baseline in Profile of Mood States (POMS) — 5.75; 12.46; 18.55; 4.08 units on a scale
Phase 2 N=199 The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking
Cannabis Intoxication
Primary: Change in Composite Drive Score (CDS) From Pre-smoking Simulation — -.09; .12; .01; -.17 z-score — p=<0.001
Phase 3 N=8 Vaping THC From Electronic Cigarettes
Marijuana Dependence
Primary: Mean Delivered and Retained Doses — 0.016; 0.018; 0.026 grams (g)
N/A N=99 Cannabis Effects on Driving-related Skills of Young Drivers
Psychomotor Impairment
Primary: Psychomotor Impairment (Driving) — 3.38; -1.54 change in kph
Phase 1 N=26 Behavioral Pharmacology of Cannabis and Nicotine
Cannabis · Nicotine
Primary: Amount of Nicotine (mL of Smoke/Vapor) Inhaled — 0; 489.0; 1814.0; 1401.0 Volume in mL
Phase 2 N=66 Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
Cannabis Dependence · Cannabis Withdrawal
Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…
N/A N=14 Pharmacotoxicology of Trichloroethylene Metabolites
Congenital Lactic Acidosis
Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023
Phase 4 N=14 Effects of Pregnancy-associated Hormones on THC Metabolism in Women
Pregnancy Related · Cannabis Use
Primary: Dronabinol Exposure — 7.0; 5.6; 5.1; 5.0 nM*h — p=>0.05
N/A N=25 Impact of Reduced Cannabis Use on Functional Outcomes
Cannabis · Cannabis Use
Primary: Number of Participants Who Complete the Baseline Assessment — 18 Participants
N/A N=67 Clinical Trial Tobacco Marijuana
Cannabis Use Disorder · Tobacco Use Disorder
Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33
Phase 2 N=10 Repeated Cannabis Administration on Experimental Pain and Abuse Liability
Cannabis · Pain · Tolerance
Primary: Change in Cold Pressor Test (CPT) Latency — 21.40; 10.94; 2.07; 15.17 percent change from Day 1 baseline
Early Phase 1 N=60 Individual Differences in Drug Response
Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Primary: Change From Baseline in Profile of Mood States (POMS) — 2.58; 4.28; 8.25; 0.7 units on a scale
Phase 1 N=22 Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs
Drug-Interactions
Primary: Losartan Area Under the Curve (AUC) in Plasma — 164; 185; 289 h*ng/mL
Early Phase 1 N=30 Behavioral Effects of Pregabalin and Cannabis
Cannabis-use Disorders
Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…
Phase 1 N=24 Opioid and Cannabinoid Pharmacokinetic Interactions
Pain
Primary: Disposition Kinetics of Morphine and Oxycodone Before and After Cannabis Use — 1.64; -1.11; 0.9; 0.99 Geometric Mean Ratio
Phase 1 N=33 Behavioral Pharmacology of THC and Alpha-pinene
THC · Alpha-pinene
Primary: Mean Peak Change From Baseline Drug Effect as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 5.1; 67.2; 66.1 score on a scale
Phase 2 N=50 Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
Smoking, Marijuana
Primary: Mood Scale - Subscale 'Feeling High' — 4.35; 2.48; 0.39; 6.55 units on a scale VAS 1-100 mm
Phase 1 N=23 Differences in Cannabis Impairment and Its Measurement Due to Route of Administration
Behavioral Pharmacology of Cannabis
Primary: Tetrahydrocannabinol (THC) Concentration in Blood — 0; 1.78; 3.06; 0 ng/ml
Phase 1 N=35 Behavioral Pharmacology of THC and D-limonene
D-limonene and THC Pharmacodynamics
Primary: Mean Peak Change From Baseline Anxiety as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 13.8; 18.7; -1.9 score on a scale
N/A N=98 Effects of Inhaled Cannabis on Driving Performance
Alcohol Drinking · Cannabis
Primary: Driving Performance — 0.26; 0.42; 0 cm
Phase 2 N=70 Treatment for Cannabis Withdrawal and Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg
N/A N=27 Cannabis Use in Cancer Patients
Solid Tumor, Adult
Primary: Likelihood of Accruing Participants: Feasibility of Enrollment — 27; 24 Participants
Phase 2 N=5 Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain
Cannabis · HIV Neuropathy · Pain Syndrome
Primary: Phase 1 - Numerical Pain Rating Scale (NPRS) — 2.2; 2.6; 2.8; 1.4 units on a scale
Phase 1 N=10 Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
Cannabis Use Disorder
Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day
Phase 2 N=25 Effects of Dronabinol (Oral THC) on Cannabis Use
Marijuana Smoking
Primary: Marijuana Self-administration - Progressive Ratio — 5.2; 4.5; 4.4 Progressive Ratios Completed
N/A N=36 Cannabidiol Effects on Blood Alcohol Level and Intoxication
Alcohol Use Disorder
Primary: Breath Alcohol Concentration (BrAC) — 0.065; .067; .070 g/dL
Phase 2 N=7 Pharmacotoxicology of Trichloroethylene Metabolites
Healthy
Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml
N/A N=361 Anxiety, Inflammation, Stress, and Cannabinoids
Anxiety · Anxiety Disorders · Anxiety Generalized
Primary: Change in Anxiety: Depression Anxiety Stress Scale (DASS21). — 9.38; 10.1; 10.5; 9.85 units on a scale
Phase 1 N=10 Opioid and Cannabinoid Interactions
Marijuana Usage · Opioid Use
Primary: Change in Subject-Rated Outcome - VAS Drug Liking — 3; 53.33; 58.89; 38.78 score on a scale